The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Biomarkers in lymphoma
In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, gives a brief overview of the role of biomarkers in lymphoma. Dr Diepstra covers how they can be used to determine patient prognosis and influence clinical decisions. He highlights the TARC biomarker currently being used in Hodgkin lymphoma.
